Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sesen Bio, Inc. (SESN)

0.5325   -0.01 (-1.83%) 12-07 16:00
Open: 0.54 Pre. Close: 0.5424
High: 0.5537 Low: 0.521
Volume: 478,951 Market Cap: 108(M)

Technical analysis

as of: 2022-12-07 4:25:57 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.67     One year: 0.79
Support: Support1: 0.5    Support2: 0.45
Resistance: Resistance1: 0.57    Resistance2: 0.67
Pivot: 0.54
Moving Average: MA(5): 0.54     MA(20): 0.54
MA(100): 0.58     MA(250): 0.63
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 66.1     %D(3): 66.5
RSI: RSI(14): 45.5
52-week: High: 0.96  Low: 0.36
Average Vol(K): 3-Month: 1,123 (K)  10-Days: 1,257 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SESN ] has closed above bottom band by 16.9%. Bollinger Bands are 74.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.55 - 0.56 0.56 - 0.56
Low: 0.51 - 0.52 0.52 - 0.52
Close: 0.53 - 0.53 0.53 - 0.54

Company Description

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 30 Nov 2022
SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq

Fri, 18 Nov 2022
Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio - Nasdaq

Fri, 11 Nov 2022
Sesen Bio, Inc. to Post Q4 2022 Earnings of ($0.11) Per Share, Jefferies Financial Group Forecasts (NASDAQ:SESN) - MarketBeat

Thu, 27 Oct 2022
Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research

Fri, 14 Oct 2022
Do Analysts Agree Friday on Sesen Bio Inc (SESN) Stock's Target Price? - InvestorsObserver

Wed, 21 Sep 2022
Novartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 203 (M)
Shares Float 203 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 12.9 (%)
Shares Short 3,110 (K)
Shares Short P.Month 3,490 (K)

Stock Financials

EPS 0.33
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.81
Profit Margin (%) -5.7
Operating Margin (%) -43.3
Return on Assets (ttm) -7.5
Return on Equity (ttm) -2.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0.29
EBITDA (p.s.) -0.13
Qtrly Earnings Growth -71.5
Operating Cash Flow 10 (M)
Levered Free Cash Flow 24 (M)

Stock Valuations

PE Ratio 1.61
PEG Ratio 0
Price to Book value 0.65
Price to Sales 1.79
Price to Cash Flow 11.23

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.